Amgen

Open: 263.15 Close: 266.09 Change: 2.94

How to know if Amgen Company Inc Stock is a risky investment without reading the whole internet.

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, last, year, FDA, drug, Horizon, Therapeutics, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Amgen today and set a price target of $288.00. The word on The Street suggests a Moderate Buy consensus rating for Amgen with a $260.64 consensus rating.

Today's News

FDA panel says amgens phase ii lung cancer kras drug data is unreliable - pharmaceutical technology. Lumakras generated $285m in sales last year worldwide. Analysts offer insights on healthcare companies: Immunic (IMUX), Amgen (AMGN) and Neurocrine (NBIX) Piper Sandler analyst Christopher Raymond maintained a Buy rating on Amgen today and set a price target of $288.00. The word on The Street in general, suggests a Moderate Buy consensus rating for Amgen with a $260.64. Intuit revenue growth has been better, with a 23.6% average annual growth rate in the last three years, compared to 4.1% for Amgen. Amgen revenue will likely rise at a low single-digit average annual rate to $28 billion, based on Trefis Machine Learning analysis. Intuit stock trades at 10.2x revenues compared to its last five years average. Amgen recently announced a new manufacturing site in Ohio. Amgen Ohio will be the companys most advanced final product assembly and packaging plant, using digital and robotic technologies. Amgen Concludes Horizon Therapeutics acquisition. In premarket activity, shares of Amgen are trading at $262.50. The FDA is expected to make a decision on the Amgen drug by Dec. 4, 2023. The FDA, which generally follows the advice of its expert panels but is not bound to do so, is expected. Amgen completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash. Amgen has a reputation for attracting the best talent around. Amgen agreed to buy Horizon Therapeutics for about $27.8 billion last year. Amgen won out in a three-way tussle with Sanofi and Johnson & Johnson when it last December announced what was the biggest pharmaceutical deal of the year. Amgens Lumakras showed no significant difference in overall survival - the gold standard for cancer drugs - but Amgen said the study was not designed to demonstrate a survival benefit. The FDA is expected to make a decision on the traditional approval for Amgens drug by Dec. amgens late-stage data for lung. Amgen to present at the Morgan Stanley Global Healthcare Conference at 8:50 a.m. 9/7/2023 Amgen and Horizon Therapeutics plc (NASDAQ:HZNP) resolve the pending FTC administrative lawsuit. FTC Agreement Clears Amgen-Horizon deal with restrictions.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, last, year, FDA, drug, Horizon, Therapeutics, and the most common words in the summary are: amgen, job, stock, market, news, report, best, . One of the sentences in the summary was: The word on The Street suggests a Moderate Buy consensus rating for Amgen with a $260.64 consensus rating.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #job #stock #market #news #report #best.